Everything drug pricing and policy, every day
Plus an IQVIA assessment of the $2,000 Part D cap shows the dramatic impact on oncology patients ... and manufacturers
And an introductory look into a huge question: Will the use of medicines in Medicaid plunge when millions lose coverage?
Plus two academic papers worth reading, one raising concerns about step therapy and one raising concerns about MFN. Lots to be concerned about today!
And two links on PBMs, two on obesity, and a study that shows that cost-related nonadherence is on the wane
Plus a look at an IQVIA deep dive into a way of ensuring that 340B discounts make it directly to patients: ‘340 cards’
And looking through a fresh batch of comments on CMS IRA guidance makes clear that 340B is the elephant in the room
And the reconciliation bill is headed to a Senate vote today ... but without PBM reform or orphan-drug provisions
And IQVIA data shows the extent of the utilization management headaches for Medicare patients
And introducing a new way of segmenting the voices in the 340B debate: the (Jimmy) Buffett Rule
